-
公开(公告)号:US11897904B2
公开(公告)日:2024-02-13
申请号:US16765009
申请日:2018-11-15
发明人: Frank Memmel , Ralf Braun , Christian Waldraff , Gunter Karig , Simon Doerner-Rieping , Isolde Haeuser-Hahn , Anu Bheemaiah Machettira , Hansjoerg Dietrich , Elmar Gatzweiler , Christopher Hugh Rosinger
IPC分类号: A01N55/08 , A01N43/653 , A01N43/713 , C07D405/12 , C07D249/14 , C07D257/06 , C07D327/04 , C07D409/12 , C07D411/12 , C07D417/04 , C07C323/62 , C07F5/02
摘要: Benzoylamides of the general formula (I) are described as herbicides.
In this formula (I), B, X1 and X2 represent N, O or S(O)n.
R, Ra, Rb and Rx represent radicals such as hydrogen, halogen, (C1-C6)-alkyl, halo-(C1-C6)-alkyl, (C1-C6)-alkyloxy and cyano.-
公开(公告)号:US11746425B2
公开(公告)日:2023-09-05
申请号:US17491566
申请日:2021-10-01
发明人: Richard Kellett
IPC分类号: C25B3/23 , C06B25/34 , C25B3/25 , C07D257/06
CPC分类号: C25B3/23 , C06B25/34 , C25B3/25 , C07D257/06
摘要: A composition including copper(I) 5-nitrotetrazolate, wherein the composition has a carbon content of less than 7 weight percent, based on a total weight of the copper(I) 5-nitrotetrazolate.
-
公开(公告)号:US20220249447A1
公开(公告)日:2022-08-11
申请号:US17606720
申请日:2020-04-24
发明人: Herman O. Sintim , George Naclerio
IPC分类号: A61K31/4245 , C07D413/04 , C07D417/14 , C07D413/14 , C07D271/113 , C07D409/04 , C07D271/07 , C07D413/12 , C07D277/46 , C07D231/40 , C07D257/06 , A61K31/427 , A61K31/4439 , A61K31/4196 , A61K31/433 , A61K31/426 , A61K31/415 , A61K31/41 , A61K45/06
摘要: The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate and vancomycin-resistant S. aureus (VISA and VRSA respectively) vancomycin-resistant Enterococcusfaecalis (VRE), and Clostridioides difficile. Pharmaceutical compositions and methods for treating those infection diseases are within the scope of this invention.
-
公开(公告)号:US11339139B2
公开(公告)日:2022-05-24
申请号:US16927601
申请日:2020-07-13
申请人: CORSAIR PHARMA, INC.
IPC分类号: C07D313/00 , C07C69/712 , C07D317/40 , C07D321/00 , C07D257/06 , C07D263/24 , C07D265/30 , C07D295/088 , C07D211/60 , C07D295/145 , C07D307/20 , C07C219/16 , C07C235/20 , C07D453/02 , C07C59/54 , C07C69/734 , C07C235/34 , C07D207/08 , C07D263/26 , C07D317/34 , A61K9/70 , A61K31/165 , A61K31/216 , A61K31/335 , C07C59/31
摘要: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
-
公开(公告)号:US20220135530A1
公开(公告)日:2022-05-05
申请号:US17221863
申请日:2021-04-05
IPC分类号: C07D257/06
摘要: This disclosure shows the ability of a readily-available oxidizer to achieve oxidation of 5-amino-1H-tetrazole (5-AT) to 5-nitrotetrazole (5-NT) in high yields in a single pot synthesis. This strategy reduces the synthesis of this important energetic material down to a single step and eliminates highly sensitive diazonium and copper salt primary explosive intermediates. The overall yield of this process is 48-53% and the resultant aqueous solution of product effectively used for the preparation of nitrotetrazole-containing primary explosive DBX-1. Unlike current methods of nitrotetrazole preparation, the novel method is entirely solution-based and prepares a final solution of sodium nitrotetrazolate, never once needing to handle energetic intermediates or products, making it a much safer method of nitrotetrazole preparation.
-
公开(公告)号:US11220484B2
公开(公告)日:2022-01-11
申请号:US16481984
申请日:2018-01-30
申请人: SOLVIAS AG
发明人: Heinz Steiner
IPC分类号: C07D231/22 , C07C269/00 , C07D257/06
摘要: An economic, one-step method for the production of N-substituted aromatic hydroxylamines of formula (I) R—N(OH)—C(═O)—(O)R1 (I), with hydrogen, by catalytic hydration with possibly modified hydration catalysts in an aprotic solvent and in the presence of a halogen formic acid ester and in some cases in the presence of a base.
-
公开(公告)号:US11174560B2
公开(公告)日:2021-11-16
申请号:US16407241
申请日:2019-05-09
发明人: Richard Kellett
IPC分类号: C25B3/23 , C06B25/34 , C07D257/06
摘要: A composition including copper(I) 5-nitrotetrazolate, wherein the composition has a carbon content of less than 7 weight percent, based on a total weight of the copper(I) 5-nitrotetrazolate.
-
公开(公告)号:US11053234B2
公开(公告)日:2021-07-06
申请号:US16341113
申请日:2017-10-12
发明人: David Norman Deaton , Yu Guo , Ashley Paul Hancock , Christie Schulte , Barry George Shearer , Emilie Despagnet Smith , Eugene L. Stewart , Stephen Andrew Thomson
IPC分类号: C07D417/14 , C07D417/12 , C07C235/40 , A61K9/00 , A61K9/48 , C07D205/04 , C07D401/04 , C07D239/42 , C07D271/10 , C07D257/06 , C07D403/04 , C07D277/44 , C07D277/62 , A61P21/00 , A61P11/06 , C07D215/24 , C07D239/72 , C07D277/64 , C07D471/04
摘要: A compound of formula (I) wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
-
公开(公告)号:US11046666B2
公开(公告)日:2021-06-29
申请号:US16569840
申请日:2019-09-13
申请人: CORSAIR PHARMA, INC.
IPC分类号: C07D321/00 , C07D453/02 , C07D257/06 , C07C59/72 , C07C235/20 , A61K31/165 , C07C69/734 , A61K31/216 , A61K31/365 , C07D307/20 , A61K31/341 , A61K45/06 , A61K9/00 , C07D317/34 , C07C69/712 , C07D317/40 , C07C219/16 , C07D263/24 , C07D263/26 , C07D265/30 , C07D207/08 , C07D295/088 , C07D211/60 , C07D295/145 , C07C69/74 , C07C69/96 , A61K9/70
摘要: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
-
公开(公告)号:US20210179569A1
公开(公告)日:2021-06-17
申请号:US16617435
申请日:2018-05-29
申请人: BASF SE
发明人: Markus KORDES , Thomas ZIERKE , Thomas SEITZ , Ryan Louis NIELSON
IPC分类号: C07D257/06 , C07D271/113 , C07D249/14 , C07D271/08 , A01N43/82 , A01N43/713 , A01N43/653
摘要: The invention relates to benzamides of formula I, wherein Q is Q1 or Q2 or Q3 or Q4, and their use as herbicides. In said formula I, R2 is R2cR2dNC(O)NR2n—Z2, R5 is hydrogen, R1, R3, R4 and R6 represent groups such as hydrogen, halogen or organic groups such as alkyl or phenyl. The invention further refers to a composition comprising such compound and to the use thereof for controlling unwanted vegetation.
-
-
-
-
-
-
-
-
-